心脏骤停后缺氧性癫痫持续状态的特征、结局与治疗:3个队列的汇总分析
该研究汇总了心脏骤停后72小时内符合ACNS标准的确切或可能癫痫持续状态患者的个体数据,共274例,其中24例(8.8%)预后良好。排除≥2项ERC/ESICM不良预后标准后,94例患者中25%预后良好;在确切SE患者中,SE终止、放电频率更高、指南推荐治疗及左乙拉西坦和丙戊酸剂量较高与良好预后相关。
要点
- 心脏骤停后确切或可能SE患者中,无≥2项ERC/ESICM不良预后标准者约25%预后良好。
- SE发作前EEG背景连续性和较高放电频率有助于识别可能从延长治疗中获益的患者。
- 确切SE患者中SE终止、指南推荐治疗及较高剂量左乙拉西坦/丙戊酸与良好预后相关。
核心结论
- 心脏骤停后确切或可能SE患者,在无≥2项ERC/ESICM不良预后标准时,有25%的机会获得良好结局。
- SE发作前EEG背景连续性和较高放电频率有助于识别可能受益于延长治疗的患者。
研究设计与样本
- 多中心汇总分析,整合TELSTAR试验和布鲁塞尔、日内瓦两个本地注册研究的个体患者数据。
- 纳入心脏骤停后72小时内EEG符合ACNS标准的确切或可能SE患者,共274例,中位年龄66岁,女性占31%。
主要发现
- 274例患者中24例(8.8%)预后良好。
- 多变量分析显示,非运动性发作症状学和SE终止与良好恢复相关。
- 排除≥2项ERC/ESICM不良预后标准后,94例患者中25%预后良好。
- 在确切SE患者中,SE终止(12[100%] vs 20[50%],p=0.002)、较高出院频率(3 Hz[IQR 2-3] vs 2 Hz[IQR 2-3],p=0.024)、指南推荐SE治疗(12[100%] vs 28[70%],p=0.047)、较高剂量左乙拉西坦(4,250[IQR 3,750-4,500] mg vs 2,000[IQR 2,000-3,000] mg,p=0.001)和丙戊酸(4,800[IQR 3,600-5,400] mg vs 2,000[IQR 1,850-2,250] mg,p=0.032)与良好结局相关。
- 良好结局的确切或可能SE患者中,无人在SE发作前出现抑制/爆发抑制背景。
关键数值与推荐
- 确切或可能SE依据ACNS标准定义,纳入心脏骤停后72小时内EEG。
- 主要结局为3个月脑功能分类(CPC),1-2为良好,3-5为不良。
- 不良预后ERC/ESICM标准≥2项者被排除后分析。
临床怎么用
- 对于心脏骤停后SE患者,应评估ERC/ESICM不良预后标准以分层。
- 无≥2项不良预后标准者,可考虑积极抗癫痫治疗,尤其确切SE患者。
- EEG背景连续性和放电频率可用于识别可能受益于延长治疗的患者。
局限性
- 研究为汇总分析,部分数据来自注册研究,可能存在选择偏倚。
- 样本量有限,尤其良好结局患者较少。
- 治疗剂量与结局的关联可能受混杂因素影响,不能证明因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The prognostic significance and the benefits of antiseizure treatment for definite and possible status epilepticus (SE) after cardiac arrest (CA) remain debated. The study aims to identify clinical and EEG predictors of outcome in definite and possible SE after CA and to determine patient categories in which antiseizure medication is useful. METHODS: We conducted a multicenter pooled analysis of individual patient data from the Treatment of ELectroencephalographic STatus epilepticus After cardiopulmonary Resuscitation trial and 2 local registries (Brussels and Geneva). Patients with EEG patterns fulfilling the American Clinical Neurophysiology Society criteria for definite or possible SE within 72 hours after CA were included. Primary outcome was the cerebral performance category (CPC) at 3 months, dichotomized as good (CPC 1-2) or poor (CPC 3-5). Patients, clinical, EEG, and treatment characteristics were related to outcome using univariate and multivariate analyses in the whole cohort and separate for patients without ≥2 poor outcome European Resuscitation Council (ERC)/European Society of Intensive Care Medicine (ESICM) criteria. This latter group of patients was further divided into 2 subgroups: those with definite SE and those with possible SE. RESULTS: Of 274 patients (median age 66 [interquartile range (IQR) 55-75], 31% female) with definite or possible SE, 24 (8.8%) had good recovery. In multivariate analysis, nonmotor semiology and SE cessation were associated with good recovery. After exclusion of patients with ≥2 poor outcome ERC/ESICM criteria (180 patients), we included 94 patients (52 definite SE and 42 possible SE), 25% having good outcome. In definite SE, SE cessation (12 [100%] vs 20 [50%], p = 0.002), higher discharge frequency (3 Hz [IQR 2-3] vs 2 Hz [IQR 2-3], p = 0.024), guideline-recommended SE treatment (12 [100%] vs 28 [70%], p = 0.047), and higher doses of levetiracetam (4,250 [IQR 3,750-4,500] mg vs 2,000 [IQR 2,000-3,000] mg, p = 0.001) and valproic acid (4,800 [IQR 3,600-5,400] mg vs 2,000 [IQR 1,850-2,250] mg, p = 0.032) were associated with favorable outcome. None of the definite or possible SE patients with good outcome had a suppressed/suppression-burst background before SE onset. DISCUSSION: Patients with postanoxic definite or possible SE have a 25% chance of good outcome in the absence of ≥2 poor outcome ERC/ESICM factors. EEG background continuity before SE onset and higher discharge frequency contribute to the identification of patients who may benefit from protracted treatment.
引用
- De Stefano P, Hofmeijer J, Quintard H, et al. Features, Outcome, and Treatment of Postanoxic Status Epilepticus: Pooled Analysis of 3 Cohorts. Neurology. 2025. PMID: 40720710. doi:10.1212/WNL.0000000000213913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。